Turnover Rate of Autologous Plasma Fibrinogen-¹⁴C in Subjects with Coronary Thrombosis^[*]

Summary

The plasma concentration of fibrinogen increases as a statistical function of the occurrence of coronary heart disease. This increase in concentration is associated with a grossly enhanced rate of turnover of the molecule. A mean turnover rate of 0.260 mg/ ml/day of plasma fibrinogen in the young normal subject increases to 0.378 at 53 yrs of age in the normal group and to 0.466 in the same age group with coronary artery disease. The increased rate of turnover signifies an increase in both the rate of biosynthesis and the rate of utilization of the soluble precursor of the clot forming protein, fibrin.

An increase in the concentration of plasma fibrinogen and in the rate of turnover also occur as a statistical function of age. Occurrence of occlusive vascular phenomenon in the same age group served to further enhance these changes. The regression data indicate that the metabolic changes are progressive and that the normal subject will eventually display, in association with the development of coronary thrombosis, a metabolic abnormality equivalent to the patient with coronary heart disease.

Evidence is discussed which indicates that part or all of the enhanced utilization of fibrinogen may be attributed to an increase in the conversion of fibrinogen to fibrin. The relationship of the enhanced rate of turnover of fibrinogen to atherogenesis and thrombosis is reviewed.

^* This study has been supported by the Santa Barbara Chapter of the California Heart Association, the Minnesota Heart Association, the Iowa Heart Association, and the National Institutes of Health, U.S. Public Health Service.

¹ Present adress: Bio-Science Laboratories, 7600 Tyrone Avenue, Van Nuys, California 91405.

• References

• 1 Pilgeram L.O, Pickart L.R. Turnover rate of human plasma fibrinog A function of aging and arteriosclerosis. Gerontologist 1964; 4: 34 Circulation 30:24(1964); Fed. Proc 30: 24 (1965)
• 2 Amris A, Amris G.J. Turnover and distribution of ¹³¹iodine-labelled human fibrinogen. Thrombos. Diathes haemorrh. (Stuttg.) 1964; 11: 404
• 3 Schram A.C, Pilgeram L.O. Correlation of activity changes in blood coagulation factors with human arteriosclerosis. Circulation 1959; 20: 991
• 4 Pilgeram L.O, Schram A.C, Mills D. Specificity of plasma fibrinogen changes for atherosclerosis. Circulation 1960; 22: 668
• 5 Pilgeram L.O. The relation of plasma fibrinogen concentration changes to human aterosclerosis. J. appl. Physiol 1961; 16: 660
• 6 Steinmann B. Über Beziehungen zwischen Cholesterinund Fibrinogen-Gehalt. Thromboembolien und Atherosklerose. Gerontología 1965; 10: 100
• 7 Pilgeram L.O, Pickart L.R, Bandi Z. Fatty acid control of fibrinogen turnover in aging and arteriosclerosis. Proceedings Seventh International Congress of Gerontology, Vienna, Austria 1966; 2: 325
• 8 Hampton J.W, Mantooth J, Brandt E.N, Wolf Jr. S.G. : Plasma fibrinogen patterns in patients with coronary atherosclerosis. Circulation 1966; 34: 1098
• 9 Spittel J.A, Pacuzzi G.A, Thompson J.H, Owren G.A. Acceleration of early stages of coagulation in certain patients with occlusive arterial or venous diseases : Use of a modified thromboplastin generation test to evaluate clot acceleration. Proc. Mayo Clin 1960; 35: 37
• 10 Pascuzzi C.A, Spittel Jr. J.A, Thompson Jr. J.H, Owren Jr. C.A. Thromboplastin generation accelerator, a newly recognized component of the blood coagulation mechanism present in excess in certain thrombotic states. J. clin. Invest 1961; 40: 1006
• 11 Murphy E.A, Mustard J.F. Coagulation tests and platelet economy in atherosclerotic and control subjects. Circulation 1962; 25: 114
• 12 Pilgeram L.O, Schram A.C, Loegering D.A. Elevation of plasma antithrombin in the aging arteriosclerotic subject. J. appl. Physiol 1963; 18: 329
• 13 Commers L.R, Pilgeram L.O. Oxalate induced correction of the plasma antithromboplastin deficiency in the aging arteriosclerotic subject. Thrombos. Diathes. haemorrh. (Stuttg.) 1964; 10: 350
• 14 Penick G.D, Dejanov I.I, Roberts H.R, Webster W.P. Elevation of factor VIII in hyper - coagulable states. Diffuse Intravascular Clotting. F. Koller: F. K. Schattauer (Stuttg.); 1965: 39
• 15 Pilgeram L.O, Pickart L.R. Control of fibrinogen biosynthesis: The role of free fatty acid. J. Atheroscler. Res 1968; 8: 155
• 16 Jarnum S. A modified extraction method for determination of Evans blue. Scand. J. clin. Lab. Invest 1959; 11: 332
• 17 Gordon A.H. Factors influencing plasma protein synthesis by the liver. Biochem. J 1964; 90: 18
• 18 Pickart L.B, Pilgeram L.O. The role of thrombin in fibrinogen biosynthesis. Thrombos. Diathes. haemorrh. (Stuttg.) 1967; 17: 358
• 19 Penn N.W, Mandeles S, Anker H.S. On the kinetics of turnover of serum albumin. Biochim. biophys. Acta (Amst.) 1957; 26: 349
• 20 Madden R.E, Gould R.G. Turnover rate of plasma fibrinogen. Fed. Proc 1952; 11: 252
• 21 Hammond J.D, Verel S.D. Observations on the distribution and biological halflife of human fibrinogen. Brit. J. Haemat 1959; 5: 431
• 22 Takeda Y, Chen A.Y. Fibrinogen metabolism and distribution in patients with the nephrotic syndrome. J. Lab. clin. Med 1967; 70: 678
• 23 Katz J, Bosenfeld S, Sellers A.L. Role of the kidney in plasma albumin catabolism. Amer. J. Physiol 1960; 198: 814
• 24 Gajewski J, Alexander B. Effect of epsilon amino caproic acid on the turnover of labeled fibrinogen in rabbits. Circulat. Res 1963; 13: 432
• 25 Lewis J. Effect of epsilon amino caproic acid (EACA) on survival of fibrinogen I¹³¹ and on fibrinolytic and coagulation factors in dogs. Proc. Soc. exp. Biol 1963; 114: 777
• 26 Galasinski W, Worowski K, Niewiarowski S, Franecki G. Turnover of ¹³¹I - fibrinogen in mercury chloride intoxicated dogs. Thrombos. Diathes. haemorrh. (Stuttg.) 1967; 18: 268
• 27 Adelson E, Bheingold J.J, Parker O, Buenaventura A, Crosby W.H. Platelet and fibrinogen survival in normal and abnormal states of coagulation. Blood 1961; 17: 267
• 28 Lewis J.H, Ferguson E.E, Schoenfeld C. Studies concerning the turnover of fibrinogen I¹³¹ in the dog. J. Lab. clin. Med 1961; 58: 247
• 29 von Rokitansky K. AT Handbuch der Pathologischen Anatomie. Braunmuller und Seidel, Wien 1842-1846 Vol1-3
• 30 Clark E, Graef I, Chassis H. Thrombosis of the aorta and coronary arteries with special reference to fibrinoid lesions. Arch. Path 1936; 22: 183
• 31 Duguid J.B. Thrombosis as a factor in the pathogenesis of coronary atherosclerosis. J. Path. Bact 2071 55: 946
• 32 Harrison C.V. Experimental pulmonary arteriosclerosis. J. Path. Bact 1948; 60: 289
• 33 Duguid J.B. Pathogenesis of atherosclerosis. Lancet 1949; II: 925
• 34 McLetchie N.G.B. The pathogenesis of atherosclerosis. Amer. J. Path 1952; 28: 413
• 35 Thomas W.A, O’Neal B.M, Lee K.T. Thromboembolism, pulmonary arteriosclerosis and fatty meals. Arch. Path 1956; 61: 380
• 36 Filshie I, Scott G.V.D. The organization of experimental venous thrombi. J. Path. Bact 1958; 76: 71
• 37 Hand B.A, Chandler A.G. Atherosclerotic metamorphosis of autologous pulmonary thromboemboli in the rabbit. Amer. J. Path 1962; 40: 469
• 38 Murray N, Schrodt G.B, Berg H.F. The enzymatic induction of atherosclerosis. Arch. Path 1441; 72: 965
• 39 Gonzalez I.E, Ehrenfeld W.K, Vermeulen F. Relations between circulating blood and atheroma forming on dacron prostheses. Circulation 1967; 36: 13
• 40 Pilgeram L.O, Greenberg D.M. Susceptibility to experimental atherosclerosis and methylation of ethanolamine-1, 2 -C¹⁴ to phosphatidyl choline. Science 1954; 120: 760
• 41 Astrup T. The relation between formation and lysis of fibrin in the body. Diffuse Intravascular Clotting. F. Koller: F. K. Schattauer Stuttg.; 1966: 71
• 42 Astrup T. Biologie des Plasmins-Purpura Schönlein-Henoch–Erythrozytäre Gerinnungs- aktivität. F. K. Schattauer: Stuttg.; 1967: 5